Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors

NCT03583125 is registered in ClinicalTrials.gov with Taizhou EOC Pharma Co., Ltd. as lead sponsor.

NCT NCT03583125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03583125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors
Lead sponsor
Taizhou EOC Pharma Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
May 29, 2018
Completion date
November 29, 2020
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor